

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016



## **SAFETY DATA SHEET**

### **SECTION 1: Identification of the substance/mixture and of the company/undertaking**

#### **1.1. Product identifier**

**Product Name:** Tarka Hard Capsules  
**Synonyms:** Tarka (Trandolapril/Verapamil) Hard Capsules; Tarka capsules; Tarka 2 mg/180 mg Hard Capsule; Tarka Slow Release Capsules  
**Trade name:** Tarka  
**List Number:** N863

#### **1.2. Relevant identified uses of the substance or mixture and uses advised against**

**Recommended use:** Pharmaceuticals

#### **1.3. Details of the supplier of the safety data sheet**

**Supplier:** Manufactured for:  
AbbVie Inc.  
1 North Waukegan Road  
North Chicago, IL 60064  
USA  
+1-847-932-7900  
**Customer Service Telephone:** 1-800-255-5162 (US and Canada only)  
+1-847-937-7433  
**E-mail Address:** AbbVie.SDS@abbvie.com

#### **1.4. Emergency telephone number**

**Emergency Telephone:** CHEMTREC: 1(800) 424-9300 (in USA and Canada)  
or +1-703-527-3887 (international)

### **SECTION 2: Hazards identification**

#### **2.1. Classification of the substance or mixture**

**Regulation (EC) No 1272/2008**

##### **General Note**

<b>Acute oral toxicity</b>	Category 4
<b>Skin corrosion/irritation</b>	Category 2
<b>Serious eye damage/eye irritation</b>	Category 2
<b>Specific target organ systemic toxicity (single exposure)</b>	Category 3
<b>Chronic aquatic toxicity</b>	Chronic toxicity 3

**Classification according to EU Directives 67/548/EEC or 1999/45/EC**

**Indication of danger:** Xn - Harmful  
Xi - Irritant

**Product Name:**

**Tarka Hard Capsules**

**Issued:**

**May-16-2016**

**Risk Phrases:**

R22 - Harmful if swallowed

R36/37/38 - Irritating to eyes, respiratory system and skin

R52 - Harmful to aquatic organisms

R53 - May cause long-term adverse effects in the aquatic environment

## 2.2. Label elements



**Signal Word:**

Warning

**Hazard Statements:**

H302 - Harmful if swallowed

H315 - Causes skin irritation

H319 - Causes serious eye irritation

H335 - May cause respiratory irritation

H412 - Harmful to aquatic life with long lasting effects

**Precautionary Statements**

P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P302 + P352 - IF ON SKIN: Wash with plenty of soap and water

P304 + P340 - IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing

P312 - Call a POISON CENTER or doctor/physician if you feel unwell

P273 - Avoid release to the environment

## 2.3. Other hazards

Not determined

## **SECTION 3: Composition/information on ingredients**

Chemical Name	Weight-%	EINECS/ELINCS Number	EEC Classification	EU - GHS Substance Classification	REACH Reg. No
Sodium Alginate 9005-40-7	20-40	NA		Not Hazardous*	No data available
Verapamil Hydrochloride 152-11-4	20-30	Present	T, R25; Xi, R36/37/38; R52, 53	STOT SE 3 (H335) Skin Irrit. 2 (H315) Eye Irrit. 2 (H319) Acute Tox. 3 (H301) Aquatic Chronic 3 (H412)	No data available
Cellulose Microcrystalline 9004-34-6	5-20	Present		Not Hazardous*	No data available
Lactose monohydrate 10039-26-6	5-20	NA		Not Hazardous*	No data available

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

Kollidon 9003-39-8	1-10	NA		Not Hazardous*	No data available
Starch 9005-25-8	1-10	Present		Not Hazardous*	No data available
Water 7732-18-5	1-10	Present		Not Hazardous*	No data available
Hydroxypropyl Methylcellulose 9004-65-3	1-10	NA		Not Hazardous*	No data available
Titanium Dioxide 13463-67-7	0.1-1	Present		Not Hazardous*	No data available
Trandolapril 87679-37-6	0.1-1	NA	Xn, R48/22 R63	STOT RE 2 (H373) Repr. 2 (H361)	No data available

Not Hazardous\* - Based on available data, not classified as hazardous according to the criteria of the Globally Harmonized System.

**For the full text of the R-phrases mentioned in this Section, see Section 16**

**For the full text of the H-Statements mentioned in this Section, see Section 16**

## **SECTION 4: First aid measures**

### **4.1. Description of first aid measures**

**Eye Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Skin Contact:** Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Inhalation:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Ingestion:** Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

**Protection of First-aiders:** Use personal protective equipment

### **4.2 Most important symptoms and effects, both acute and delayed**

**Signs and Symptoms** None known from occupational exposure. Clinical data suggests the following: Allergic reactions nausea, slow heart rate, decreased blood pressure, headaches, fast heart rate, tingling in the extremities, abnormal liver function, abnormal kidney function, edema, dizziness, flushing, numbness,

**Medical Conditions Aggravated by Exposure** None known from occupational exposure. Data suggest any pre-existing ailments in the following organs: cardiovascular system, liver, or hematopoietic system. gastrointestinal system, kidney, Nervous System Hypersensitivity to the material and/or similar materials.

### **4.3. Indication of any immediate medical attention and special treatment needed**

**Notes To Physician:** Treat symptomatically

## **SECTION 5: Firefighting measures**

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

### **5.1. Extinguishing media**

**Suitable Extinguishing Media:** Use extinguishing agent suitable for type of surrounding fire

**Unsuitable Extinguishing Media:** Not determined

### **5.2. Special hazards arising from the substance or mixture**

**Special Exposure Hazards:** Not determined

### **5.3. Advice for firefighters**

**Protective Equipment and Precautions for Firefighters:** As in any fire, wear self-contained breathing apparatus and full protective gear

## **SECTION 6: Accidental release measures**

### **6.1. Personal precautions, protective equipment and emergency procedures**

**Personal Precautions:** For personal protection see section 8.

### **6.2. Environmental precautions**

**Environmental Precautions:** Contain material and prevent release to waterways or soil.

### **6.3. Methods and material for containment and cleaning up**

**Methods for Cleaning Up:** Recover product and place in an appropriate container for disposal.

### **6.4. Reference to other sections**

Refer to Sections 8, 12, and 13 for further information.

## **SECTION 7: Handling and storage**

### **7.1. Precautions for safe handling**

Handle in accordance with good industrial hygiene and safety practice.

### **7.2. Conditions for safe storage, including any incompatibilities**

Store according to label instructions.

### **7.3. Specific end use(s)**

**Recommended use:** Pharmaceuticals

## **SECTION 8: Exposure controls/personal protection**

### **8.1. Control parameters**

**Exposure limits:**

Chemical Name	Employee Exposure Limit	Skin Notation
---------------	-------------------------	---------------

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

Sodium Alginate 9005-40-7	Not applicable	None
Verapamil Hydrochloride 152-11-4	60 mcg/m <sup>3</sup> TWA	None
Cellulose Microcrystalline 9004-34-6	Not applicable	None
Lactose monohydrate 10039-26-6	Not applicable	None
Kollidon 9003-39-8	Not applicable	None
Starch 9005-25-8	Not applicable	None
Water 7732-18-5	Not applicable	None
Hydroxypropyl Methylcellulose 9004-65-3	Not applicable	None
Titanium Dioxide 13463-67-7	Not Applicable	None
Trandolapril 87679-37-6	2 mcg/m <sup>3</sup> TWA	None

Chemical Name	ACGIH TLV	France	German MAK	Ireland	Italy
Sodium Alginate 9005-40-7	10 mg/m <sup>3</sup> , total dust; 3 mg/m <sup>3</sup> respirable particulate				
Cellulose Microcrystalline 9004-34-6	10 mg/m <sup>3</sup> TWA	TWA: 10 mg/m <sup>3</sup>		20 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)	
Kollidon 9003-39-8	10 mg/m <sup>3</sup> for nuisance dust; 3 mg/m <sup>3</sup> respirable particulate				
Starch 9005-25-8	10 mg/m <sup>3</sup> TWA			30 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)	
Hydroxypropyl Methylcellulose 9004-65-3	10 mg/m <sup>3</sup> total dust; 3 mg/m <sup>3</sup> respirable dust				
Titanium Dioxide 13463-67-7	10 mg/m <sup>3</sup> TWA	TWA: 10 mg/m <sup>3</sup>		30 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)	

Chemical Name	The Netherlands	Spain	Switzerland	UK OEL/MEL
Cellulose Microcrystalline 9004-34-6		10 mg/m <sup>3</sup> (TWA)	3 mg/m <sup>3</sup> (TWA)	20 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)
Starch 9005-25-8		10 mg/m <sup>3</sup> (TWA)	3 mg/m <sup>3</sup> (TWA)	30 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)
Titanium Dioxide 13463-67-7		10 mg/m <sup>3</sup> (TWA)	3 mg/m <sup>3</sup> (TWA)	30 mg/m <sup>3</sup> (STEL) 12 mg/m <sup>3</sup> (STEL) 10 mg/m <sup>3</sup> (TWA) 4 mg/m <sup>3</sup> (TWA)

## 8.2. Exposure controls

### Engineering Controls:

No special provisions are required under normal product use conditions.  
 Use inside a process enclosure when handling the bulk formulation.

### Respiratory Protection:

Respiratory protection is not needed during normal product use. When handling the bulk formulation, an approved respirator (i.e. NIOSH, EN, etc.) should be worn when exposures are expected to exceed the applicable limits.

<b>Product Name:</b>	<b>Tarka Hard Capsules</b>
<b>Issued:</b>	<b>May-16-2016</b>
<b>Eyes:</b>	Eye protection not needed during typical product use conditions. Wear eye protection as appropriate when handling the bulk formulation.
<b>Gloves:</b>	Gloves not required during normal product use conditions. Wear impervious gloves when handling the bulk formulation.
<b>Other PPE Data:</b>	Wear appropriate body coverings if contact may occur.
<b>Environmental Exposure Controls:</b>	Not determined

## **SECTION 9: Physical and chemical properties**

### **9.1. Information on basic physical and chemical properties**

<b>Appearance:</b>	Pink Capsule
<b>Odor:</b>	Not determined
<b>Odor Threshold:</b>	Not determined
<b>pH:</b>	Not determined
<b>Boiling Pt. @ 760 mm Hg (°C):</b>	Not determined
<b>Melting/Freezing Point (°C):</b>	Not determined
<b>Flash Point (°C):</b>	Not determined
<b>Evaporation Rate at 20°C:</b>	Not determined
<b>Flammability (Solid):</b>	Not determined
<b>Lower Explosive Limit:</b>	Not determined
<b>Upper Explosive Limit:</b>	Not determined
<b>Vapor Pressure (mm Hg):</b>	Not determined
<b>Vapor Density (Air = 1):</b>	Not determined
<b>Specific Gravity:</b>	Not determined
<b>Solubility(ies):</b>	Not determined
<b>Partition coefficient:</b>	Not determined
<b>n-octanol/water</b>	
<b>Autoignition Temp. (°C):</b>	Not determined
<b>Decomposition temperature (°C):</b>	Not determined
<b>Viscosity (centipoise):</b>	Not determined
<b>Explosion Severity:</b>	Not determined
<b>Oxidizer Properties:</b>	Not determined

### **9.2. Other information**

Not determined

## **SECTION 10: Stability and reactivity**

### **10.1. Reactivity**

Not determined

### **10.2. Chemical stability**

Stable under normal conditions

### **10.3. Possibility of hazardous reactions**

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

**Hazardous reactions:** Not determined

**10.4. Conditions to avoid**

Not determined

**10.5. Incompatible materials**

Not determined

**10.6. Hazardous decomposition products**

Carbon oxides, Nitrogen oxides (NOx)

**SECTION 11: Toxicological information**

**11.1. Information on toxicological effects**

**Routes of Exposure:**

**Oral:** Clinical Route  
**Dermal:** Not determined  
**Inhalation:** Not determined

**Acute Toxicity - Oral:** Data for component (s) given below:

Chemical Name	Acute Test	Value	Units	Species
Sodium Alginate 9005-40-7	LD50 >	5000	mg/kg	Rats
Verapamil Hydrochloride 152-11-4	LD50 =	108 140 163 >400	mg/kg	Rats Guinea Pigs Mice Dogs
Cellulose Microcrystalline 9004-34-6	LD50 >	5000	mg/kg	Rats
Lactose monohydrate 10039-26-6	LD50 >	10000	mg/kg, for a similar material	Rats
Kollidon 9003-39-8	LD50 = LD50 >	100000 1040 40000	mg/kg	Rats Rabbits Mice
Hydroxypropyl Methylcellulose 9004-65-3	LD50 >	2250	mg/kg	Rats
Trandolapril 87679-37-6	LD50 =	3990 5000 2000	mg/kg	Mice Rats Dogs

**Acute Toxicity - Dermal:** Data for component (s) given below:

Chemical Name	Acute Test	Value	Units	Species
Cellulose Microcrystalline 9004-34-6	LD50 >	2000	mg/kg	Rabbits

**Acute Toxicity - Inhalation:** Data for component (s) given below:

Chemical Name	Test	Value	Units	Species
Cellulose Microcrystalline 9004-34-6	LC 50 >	5800	mg/m <sup>3</sup> , 4 hour	Rats

**Other Toxicology Data:** Data for component (s) given below:

Chemical Name	Test Type	Value	Units	Species	Comments
Verapamil Hydrochloride 152-11-4	LD50 (sc) =	68-107	mg/kg	Mice Rats	None
Trandolapril 87679-37-6	LD50 (ip) =	1420 - 1435 1285 - 1330	mg/kg	Rats Mice	None

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

**Corrosivity** Not determined

**Dermal Irritation:** Active Ingredient(s): May be a skin irritant.

**Eye irritation** Active Ingredient : May be an eye irritant.

**Sensitization** Not determined

**Toxicokinetics/Metabolism:** Not determined

**Target Organ Effects** Active Ingredient : May cause respiratory tract irritation  
Data for component (s) given below:

Chemical Name	Target Organs:	Species	Dosage	Units	Route	Duration
Verapamil Hydrochloride 152-11-4	Eyes	Dogs	60	mg/kg	Oral	12 weeks
Titanium Dioxide 13463-67-7	Lungs	Rats	10,000	mg/L	Inhalation	2 years
Trandolapril 87679-37-6	Kidney	Rats Dogs	> = 0.25 > 25	mg/kg	Oral	Variable exposure periods

**Reproductive Effects** Active Ingredient : In animals adverse reproductive effects include: maternal toxicity, maternal toxicity.  
Data for component (s) given below:

Chemical Name	Species	Dosage	Units	Route	Duration
Trandolapril 87679-37-6	Rabbits	> = 0.4	mg/kg	Oral	During Gestation

**Carcinogenicity** Active Ingredient : Not carcinogenic in animal study.  
Data for component (s) given below:

Chemical Name	Site of Tumors	Species	Dosage	Route	Units	Duration
Titanium Dioxide 13463-67-7	Lungs	Rats	250,000	Inhalation	mg/L	2 years
Trandolapril 87679-37-6	None	Mice	> 25	Oral Diet	mg/kg	18 months

**Mutagenicity:** Data for component (s) given below:

Chemical Name	Micronucleus Assay	Ames Test:	Mouse Lymphoma Assay	Chromosomal Abbr. Assay
Verapamil Hydrochloride 152-11-4	No Data.	Negative	No Data.	No Data.
Lactose monohydrate 10039-26-6	No Data.	Negative	No Data.	Negative
Trandolapril 87679-37-6	Negative	Negative	Negative	No Data.

**Aspiration hazard:** Not determined

**Notes:**

1. ALD: Approximate lethal dosage
2. LC50: Concentration in air that produces 50% mortality
3. LD50: Oral or dermal dosage that produces 50% mortality

## SECTION 12: Ecological information

### 12.1. Toxicity

Data for component (s) given below:

Chemical Name	Weight-%	LC 50 (mg/l)	Species	Duration
Verapamil Hydrochloride 152-11-4	20-30	> 4.6 < 10	Golden Orfe	96 Hours



**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

### **12.2. Persistence and degradability**

Active ingredient Not readily biodegradable

Chemical Name	Weight-%	% Degradation	Duration
Verapamil Hydrochloride 152-11-4	20-30	<20	Unspecified

### **12.3. Bioaccumulative potential**

Not determined

### **12.4. Mobility in soil**

Not determined

### **12.5. Results of PBT and vPvB assessment**

Chemical safety report is not required for this substance/product.

### **12.6. Other adverse effects**

Do not allow undiluted material or large quantities to reach groundwater, bodies of water or sewer system.

Notes:

1. EC50: Concentration in water that produces 50% mortality in *Daphnia* sp.
2. LC50: Concentration in water that produces 50% mortality in fish.
3. EbC50/ErC50: Concentration in water that produces 50% inhibition of growth and in algae.

## **SECTION 13: Disposal considerations**

### **13.1. Waste treatment methods**

**Waste Disposal Methods:** Disposal should be made in accordance with country, federal, state and local regulations.

## **SECTION 14: Transport information**

### **ADR, DOT, ICAO/IATA, IMDG/IMO**

**Status:** Not regulated

**14.1. UN number** Not applicable  
**14.2. Proper shipping name:** Not applicable  
**14.3. Hazard class:** Not applicable  
**14.4. Packing group:** Not applicable  
**14.5. Environmental hazard:** Not applicable  
**14.6. Special provisions:** Not applicable  
**14.7. Transport in bulk** Not applicable  
**according to Annex II of**  
**MARPOL 73/78 and the IBC**  
**Code:**

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

## SECTION 15: Regulatory information

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

#### International Inventories

Chemical Name	EINECS/ ELINCS	TSCA	DSL	NDSL	PICCS
Sodium Alginate 9005-40-7	-	-	-	Not listed	-
Verapamil Hydrochloride 152-11-4	Present	-	X	Not listed	-
Cellulose Microcrystalline 9004-34-6	Present	X	X	Not listed	X
Lactose monohydrate 10039-26-6	-	-	-	Not listed	-
Kollidon 9003-39-8	-	X	X	Not listed	X
Starch 9005-25-8	Present	X	X	Not listed	X
Water 7732-18-5	Present	X	X	Not listed	X
Hydroxypropyl Methylcellulose 9004-65-3	-	X	X	Not listed	X
Titanium Dioxide 13463-67-7	Present	X	X	Not listed	X
Trandolapril 87679-37-6	-	-	-	Not listed	-

Chemical Name	ENCS	ISHL	IECSC	AICS	KECL	New Zealand
Sodium Alginate 9005-40-7	-	-	-	-	-	
Verapamil Hydrochloride 152-11-4	-	-	-	X	-	HSR007000
Cellulose Microcrystalline 9004-34-6	Present	-	X	X	Present	
Lactose monohydrate 10039-26-6	-	-	X	-	-	
Kollidon 9003-39-8	Present	-	X	X	Present	
Starch 9005-25-8	Present	-	X	X	Present	
Water 7732-18-5	-	-	X	X	Present	
Hydroxypropyl Methylcellulose 9004-65-3	Present	-	X	X	Present	
Titanium Dioxide 13463-67-7	Present	-	X	X	Present	
Trandolapril 87679-37-6	-	Present	-	-	-	

#### Legend

**EINECS/ELINCS** - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDSL** - Canadian Domestic Substances List/Non-Domestic Substances List

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**ISHL** - Japan Industrial Safety and Health Law

**IECSC** - China Inventory of Existing Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**KECL** - Korean Existing and Evaluated Chemical Substances

#### Carcinogenicity Rating:

Chemical Name	Weight-%	NTP:	IARC:	ACGIH:
Sodium Alginate	20-40	Not listed	Not listed	Not listed
Verapamil Hydrochloride	20-30	Not listed	Not listed	Not listed
Cellulose Microcrystalline	5-20	Not listed	Not listed	Not listed

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

Lactose monohydrate	5-20	Not listed	Not listed	Not listed
Kollidon	1-10	Not listed	Not listed	Not listed
Starch	1-10	Not listed	Not listed	A4 - Not Classifiable as a Human Carcinogen
Water	1-10	Not listed	Not listed	Not listed
Hydroxypropyl Methylcellulose	1-10	Not listed	Not listed	Not listed
Titanium Dioxide	0.1-1	Not listed	Not listed	A4 - Not Classifiable as a Human Carcinogen
Trandolapril	0.1-1	Not listed	Not listed	Not listed

### **SARA 313 Information**

Chemical Name	Weight-%	SARA 313 Chemical:	CERCLA RQ/SARA EHS RQ (lbs):	SARA EHS TPQ (lbs):
Sodium Alginate	20-40	No	Not applicable	Not applicable
Verapamil Hydrochloride	20-30	No	Not applicable	Not applicable
Cellulose Microcrystalline	5-20	No	Not applicable	Not applicable
Lactose monohydrate	5-20	No	Not applicable	Not applicable
Kollidon	1-10	No	Not applicable	Not applicable
Starch	1-10	No	Not applicable	Not applicable
Water	1-10	No	Not applicable	Not applicable
Hydroxypropyl Methylcellulose	1-10	No	Not applicable	Not applicable
Titanium Dioxide	0.1-1	No	Not applicable	Not applicable
Trandolapril	0.1-1	No	Not applicable	Not applicable

**Immediate Health:** Yes

**Delayed Health:** No

**Fire:** No

**Sudden Pressure:** No

**Reactivity:** No

**RCRA Status:** Not determined

**Proposition 65 Status:** Does not contain chemicals known to the state of California to cause cancer or reproductive harm.

Component	Weight-%	Proposition 65 Listed Materials
Titanium Dioxide 13463-67-7 ( 0.1-1 )	0.1-1	carcinogen, 9/2/2011 (airborne, unbound particles of respirable size)

**WHMIS Hazard Class** Not determined

### **NFPA Rating:**

Health: 1

Fire: 1

Reactivity: 0

### **Notes:**

1. SARA = Superfund Amendments and the Reauthorization Act.
2. CERCLA = Comprehensive Environmental Response, Compensation and Liability Act.
3. FIFRA = Federal Insecticide, Fungicide and Rodenticide Act.
4. TSCA = Toxic Substances Control Act.
5. EC = European Community.
6. WHMIS = Canadian Workplace Hazardous Materials Information System.
7. UN GHS = United Nations Globally Harmonized System for Hazard Identification.

### **15.2. Chemical safety assessment**

Chemical safety assessment has not been conducted on the substance/product.

## **SECTION 16: Other information**

**Product Name:** Tarka Hard Capsules  
**Issued:** May-16-2016

**Risk Phrases:**

R22 - Harmful if swallowed  
R36/37/38 - Irritating to eyes, respiratory system and skin  
R52 - Harmful to aquatic organisms  
R53 - May cause long-term adverse effects in the aquatic environment

**Full text of H-Statements referred to under sections 2 and 3**

H301 - Toxic if swallowed  
H319 - Causes serious eye irritation  
H315 - Causes skin irritation  
H335 - May cause respiratory irritation  
H412 - Harmful to aquatic life with long lasting effects  
H373 - May cause damage to organs (a,b,c) through prolonged or repeated exposure if inhaled  
H361 - Suspected of damaging fertility or the unborn child if inhaled

**Document Authored By:** Global Occupational Toxicology (D-03QC)

**Issued:** May-16-2016

**Supersedes the SDS dated:** Sep-20-2011

**Disclaimer:**

*The information and recommendations contained herein are based upon tests believed to be reliable. However, AbbVie Inc. does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. AbbVie Inc. assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.*